Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
Ado-trastuzumab Emtansine 160 Mg Rec [Chas] (CDM CP17640152376430764) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved November 5, 2026 , from http://ppman.hank.ai/transparency/procedure/CP17640152376430764/by-state?code_type=CDM
“Ado-trastuzumab Emtansine 160 Mg Rec [Chas] (CDM CP17640152376430764) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/CP17640152376430764/by-state?code_type=CDM. Accessed
November 5, 2026 .
“Ado-trastuzumab Emtansine 160 Mg Rec [Chas] (CDM CP17640152376430764) by State,” HANK Price Transparency ,
accessed November 5, 2026 ,
http://ppman.hank.ai/transparency/procedure/CP17640152376430764/by-state?code_type=CDM.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
CDM · across United States
CP17640152376430764 — Ado-trastuzumab Emtansine 160 Mg Rec [Chas]
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$7,433
National median
$5,104 – $9,266
IQR (p25 – p75)
1
hospitals filing
1
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for CP17640152376430764 (CDM), with interquartile range
State Median p25 p75
NE $7,433 $5,104 $9,266